Astellas Pharma and Sanwa Kagaku Kenkyusho (SKK) will launch ARGAMATE 89.29% Granule 5.6g hyperkalemia therapy on 11 January 2013 in Japan.
ARGAMATE Granule is indicated for the treatment of hyperkalemia resulting from acute or chronic renal failure and it helps in withdrawing the unnecessary potassium in the gastrointestinal tract.
Evacuation of the excessive potassium is attained by a mechanism of exchanging potassium ions with the drug's calcium ions within the intestine.
SKK has developed ARGAMATE Granule with improved ease of swallowing and the granules are processed in such a way to reduce rough and burning sensation by having a smooth surface.
ARGAMATE Granule is a granular preparation of cation exchanger resin of calcium salt, according to SKK.
Under the strategic alliance signed between the companies in February 2012, SKK will supply ARGAMATE Granule to Astellas, which will distribute the product in Japan.
